Developer docs
API playgroundTry for free, no card

Search company profiles

Applied BioMath

Full company profile

uuid00094st

Namestring
Applied BioMath
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Applied BioMath was founded in 2013 and headquartered in Concord, Massachusetts as a specialized computational modeling and simulation services firm focused on Quantitative Systems Pharmacology (QSP) for drug development. The company built mechanistic pharmacokinetic/pharmacodynamic models and simulation platforms designed to predict clinical outcomes, optimize dosing regimens, and de-risk therapeutic development for novel targets and modalities. Its primary scientific offering was an Immunocytokine Simulation Platform developed under NIH grant funding, targeting dose and therapeutic window prediction for a challenging modality class. The company served biotech, large pharma, and CRO clients, with named engagements including CDR-Life (T cell engager CDR404) and Sanofi (Virtual Twin model for infantile-onset Pompe disease).

Applied BioMath operated primarily as a professional services firm with bespoke QSP consulting engagements, supplemented by NIH and grant-based research funding. The company's go-to-market was sales-led and relationship-driven, anchored by deep scientific expertise in modeling for bispecific antibodies, ADCs, cell and gene therapies, and other complex biologics. Pricing was quote-based and not publicly disclosed, with engagements structured around tailored modeling deliverables rather than standardized software licenses.

In December 2023, Applied BioMath was acquired by Certara (NASDAQ: CERT), a public biosimulation company with 1,550+ employees across 30+ countries and a portfolio of regulatory-grade software platforms including Simcyp, Phoenix, Pinnacle 21, and Certara IQ. Following the acquisition, Applied BioMath's team and capabilities were integrated into Certara's QSP Center of Excellence, where the combined practice now serves 275+ clients globally with 70+ QSP scientists holding 300+ combined years of domain experience and a track record of 700+ completed projects. The combined entity maintains 30-32% adjusted EBITDA margins, invests in AI-enabled QSP software (Certara IQ), and pursues regulatory-tailwind opportunities such as Non-Animal Navigator aligned with the FDA's directive to reduce animal testing.

Short descriptiontext

Applied BioMath provides Quantitative Systems Pharmacology modeling and simulation services that predict clinical outcomes and optimize dosing for novel therapeutics. Now part of Certara, it serves biotech, pharma, and CRO clients across oncology, immunology, and rare diseases.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersConcord, United States
HQ citystring
Concord
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
quantitative systems pharmacology, QSP modeling services, drug development simulation, biopharmaceutical consulting, computational pharmacology
Industry4 codes
PRIMARYHLAIALAG
Clinical Pharmacology & Pharmacometrics (Modeling & Simulation)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
Product category
Quantitative Systems Pharmacology Consulting
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1QSP Consulting Services
TypeProfessional Services
Description

Bespoke consulting engagements where Certara's team of 70+ QSP scientists provide tailored modeling and simulation services across oncology, immunology, neuroscience, rare diseases and other therapeutic areas. Engagements support target prioritization, dose determination, efficacy/toxicity assessment, and competitive evaluation.

certara.com
2Software Licensing and Subscriptions
TypeSubscription Recurring
Description

SaaS and on-premise licensing of software platforms including Certara IQ (AI-enabled QSP), Simcyp (PBPK modeling), Phoenix (PK/PD analysis), Pinnacle 21 (data standardization), D360 (scientific informatics), and others. Revenue is generated through annual subscriptions and software licenses.

certara.com
3Platform and Software Offerings
TypeSubscription Recurring
Description

Certara maintains a 30-32% adjusted EBITDA margin while investing in R&D, with plans to launch three new software offerings in Q4 2025 including AI-enabled Certara IQ for the QSP market.

investing.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details1 tier
1Enterprise software licensing with consulting services
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based / Not publicly disclosed. Annual subscription and licensing model for software platforms with bundled consulting services for enterprise clients.

certara.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Applied BioMath provides quantitative systems pharmacology (QSP) modeling and simulation services to biotechnology and pharmaceutical companies, using computational modeling combined with experimental data to predict clinical outcomes, optimize dosing, and de-risk drug development. The company also developed an Immunocytokine Simulation Platform under NIH grant funding for predicting optimal dose and therapeutic windows of immunocytokines. Following the December 2023 acquisition by Certara, Applied BioMath operates as part of Certara's QSP services division.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • QSP-derived starting dose accepted for IND and CTA for CDR-Life's T cell engager CDR404, enabling higher starting dose in clinical trial
+2 more records
Product overview1 text field

Applied BioMath is a QSP (Quantitative Systems Pharmacology) consulting company specializing in computational modeling and simulation services for drug development. Their primary offering is a simulation platform developed under NIH funding for predicting optimal dose and therapeutic window of immunocytokines. The platform aims to reduce development risks and accelerate timelines by enabling efficient screening of molecules for clinical success.

Product and service2 records
1Immunocytokine Simulation Platform
CategoryDrug Development Simulation Software
2QSP Modeling and Simulation Services
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-01
Description

Sanofi collaborated with Certara (formerly Applied BioMath) to develop a QSP-based Virtual Twin model for Pompe disease, leveraging Certara's Virtual Twin technology to compare the effects of avalglucosidase alfa vs standard of care for infantile-onset Pompe disease (IOPD) patients. The model provides mechanism-based treatment insights into heterogeneous patient populations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-08
Description

Applied BioMath was awarded a grant by the NIH to develop a simulation platform for predicting optimal dose and therapeutic window of Immunocytokines. The platform aims to reduce development risks and accelerate timelines by enabling efficient screening of molecules for clinical success. This grant was prior to the December 2023 acquisition by Certara.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CDR-Life engaged Certara's QSP team to support the development of CDR404, a T cell engager. Certara's QSP modeling and clinical pharmacology package was instrumental in enabling a higher first-in-human starting dose that was accepted for both IND and CTA. The collaboration is ongoing with plans to update the QSP model with real patient data.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Piet van der Graaf, Senior Vice President and Head of QSP at Certara, holds a professorship of Systems Pharmacology at Leiden University, facilitating academic collaboration and research output in quantitative systems pharmacology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Piet van der Graaf holds a professorship of Pediatrics at Cincinnati Children's Hospital Medical Center, supporting academic-industry collaboration in pediatric pharmacology and QSP modeling.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Applied BioMath

Quantitative Systems Pharmacology Consultingappliedbiomath.com

Applied BioMath provides Quantitative Systems Pharmacology modeling and simulation services that predict clinical outcomes and optimize dosing for novel therapeutics. Now part of Certara, it serves biotech, pharma, and CRO clients across oncology, immunology, and rare diseases.

What Applied BioMath does

Applied BioMath was founded in 2013 and headquartered in Concord, Massachusetts as a specialized computational modeling and simulation services firm focused on Quantitative Systems Pharmacology (QSP) for drug development. The company built mechanistic pharmacokinetic/pharmacodynamic models and simulation platforms designed to predict clinical outcomes, optimize dosing regimens, and de-risk therapeutic development for novel targets and modalities. Its primary scientific offering was an Immunocytokine Simulation Platform developed under NIH grant funding, targeting dose and therapeutic window prediction for a challenging modality class. The company served biotech, large pharma, and CRO clients, with named engagements including CDR-Life (T cell engager CDR404) and Sanofi (Virtual Twin model for infantile-onset Pompe disease).

Applied BioMath operated primarily as a professional services firm with bespoke QSP consulting engagements, supplemented by NIH and grant-based research funding. The company's go-to-market was sales-led and relationship-driven, anchored by deep scientific expertise in modeling for bispecific antibodies, ADCs, cell and gene therapies, and other complex biologics. Pricing was quote-based and not publicly disclosed, with engagements structured around tailored modeling deliverables rather than standardized software licenses.

In December 2023, Applied BioMath was acquired by Certara (NASDAQ: CERT), a public biosimulation company with 1,550+ employees across 30+ countries and a portfolio of regulatory-grade software platforms including Simcyp, Phoenix, Pinnacle 21, and Certara IQ. Following the acquisition, Applied BioMath's team and capabilities were integrated into Certara's QSP Center of Excellence, where the combined practice now serves 275+ clients globally with 70+ QSP scientists holding 300+ combined years of domain experience and a track record of 700+ completed projects. The combined entity maintains 30-32% adjusted EBITDA margins, invests in AI-enabled QSP software (Certara IQ), and pursues regulatory-tailwind opportunities such as Non-Animal Navigator aligned with the FDA's directive to reduce animal testing.

Applied BioMath firmographics

Firmographics
Name
Applied BioMath
Website
https://appliedbiomath.com
Company type
Private
Founded year
2013
Operating status
Acquired
Headcount range
11–50 employees
Short description
Applied BioMath provides Quantitative Systems Pharmacology modeling and simulation services that predict clinical outcomes and optimize dosing for novel therapeutics. Now part of Certara, it serves biotech, pharma, and CRO clients across oncology, immunology, and rare diseases.
Ownership category
akta.pro rank

Applied BioMath industry classification

Industry
Product category
Quantitative Systems Pharmacology Consulting
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAIALAG
Clinical Pharmacology & Pharmacometrics (Modeling & Simulation)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Quantitative systems pharmacology
  • QSP modeling services
  • Drug development simulation
  • Biopharmaceutical consulting
  • Computational pharmacology

Where Applied BioMath is headquartered

Location

Headquarters

HQ city
Concord
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Applied BioMath business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. QSP Consulting Services: Bespoke consulting engagements where Certara's team of 70+ QSP scientists provide tailored modeling and simulation services across oncology, immunology, neuroscience, rare diseases and other therapeutic areas. Engagements support target prioritization, dose determination, efficacy/toxicity assessment, and competitive evaluation.
  2. Software Licensing and Subscriptions: SaaS and on-premise licensing of software platforms including Certara IQ (AI-enabled QSP), Simcyp (PBPK modeling), Phoenix (PK/PD analysis), Pinnacle 21 (data standardization), D360 (scientific informatics), and others. Revenue is generated through annual subscriptions and software licenses.
  3. Platform and Software Offerings: Certara maintains a 30-32% adjusted EBITDA margin while investing in R&D, with plans to launch three new software offerings in Q4 2025 including AI-enabled Certara IQ for the QSP market.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise software licensing with consulting services

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Applied BioMath product offering

Product offering

Core offering

Applied BioMath provides quantitative systems pharmacology (QSP) modeling and simulation services to biotechnology and pharmaceutical companies, using computational modeling combined with experimental data to predict clinical outcomes, optimize dosing, and de-risk drug development. The company also developed an Immunocytokine Simulation Platform under NIH grant funding for predicting optimal dose and therapeutic windows of immunocytokines. Following the December 2023 acquisition by Certara, Applied BioMath operates as part of Certara's QSP services division.

Product overview

Applied BioMath is a QSP (Quantitative Systems Pharmacology) consulting company specializing in computational modeling and simulation services for drug development. Their primary offering is a simulation platform developed under NIH funding for predicting optimal dose and therapeutic window of immunocytokines. The platform aims to reduce development risks and accelerate timelines by enabling efficient screening of molecules for clinical success.

Differentiator

Problem solved

Functional benefit

Products and services

  • Immunocytokine Simulation Platform
  • QSP Modeling and Simulation Services

Quantifiable outcome

  • QSP-derived starting dose accepted for IND and CTA for CDR-Life's T cell engager CDR404, enabling higher starting dose in clinical trial
  • +2 more outcomes

Companies that use Applied BioMath

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Applied BioMath technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Applied BioMath partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • SanoficoreStrategic or Co-development Partner · 1 December 2023Sanofi collaborated with Certara (formerly Applied BioMath) to develop a QSP-based Virtual Twin model for Pompe disease, leveraging Certara's Virtual Twin technology to compare the effects of avalglucosidase alfa vs standard of care for infantile-onset Pompe disease (IOPD) patients. The model provides mechanism-based treatment insights into heterogeneous patient populations.
  • National Institutes of Health (NIH)coreStrategic or Co-development Partner · 8 August 2023Applied BioMath was awarded a grant by the NIH to develop a simulation platform for predicting optimal dose and therapeutic window of Immunocytokines. The platform aims to reduce development risks and accelerate timelines by enabling efficient screening of molecules for clinical success. This grant was prior to the December 2023 acquisition by Certara.
  • CDR-LifecoreStrategic or Co-development PartnerCDR-Life engaged Certara's QSP team to support the development of CDR404, a T cell engager. Certara's QSP modeling and clinical pharmacology package was instrumental in enabling a higher first-in-human starting dose that was accepted for both IND and CTA. The collaboration is ongoing with plans to update the QSP model with real patient data.
  • Leiden UniversityminorStrategic or Co-development PartnerPiet van der Graaf, Senior Vice President and Head of QSP at Certara, holds a professorship of Systems Pharmacology at Leiden University, facilitating academic collaboration and research output in quantitative systems pharmacology.
  • Cincinnati Children's Hospital Medical CenterminorStrategic or Co-development PartnerPiet van der Graaf holds a professorship of Pediatrics at Cincinnati Children's Hospital Medical Center, supporting academic-industry collaboration in pediatric pharmacology and QSP modeling.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Applied BioMath competitors and assessment

Company assessment

Market position

Strengths5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Applied BioMath social profiles

Digital presence

Applied BioMath financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Applied BioMath leadership team

Management profile

Number of profiles

Applied BioMath funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Applied BioMath M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Applied BioMath

What does Applied BioMath do?

Applied BioMath provides quantitative systems pharmacology (QSP) modeling and simulation services to biotechnology and pharmaceutical companies, using computational modeling combined with experimental data to predict clinical outcomes, optimize dosing, and de-risk drug development. The company also developed an Immunocytokine Simulation Platform under NIH grant funding for predicting optimal dose and therapeutic windows of immunocytokines. Following the December 2023 acquisition by Certara, Applied BioMath operates as part of Certara's QSP services division.

Is Applied BioMath a public or private company?

Applied BioMath is a private company. It is classified as corporate owned and is currently acquired.

When was Applied BioMath founded?

Applied BioMath was founded in 2013. It employs 11 to 50 people.

Where is Applied BioMath based?

Applied BioMath is headquartered in Concord, United States, in the North America region.

How does Applied BioMath make money?

Three revenue lines are on record. QSP Consulting Services are the primary driver. The others are software Licensing and Subscriptions and platform and Software Offerings.

Does Applied BioMath have an API?

No public API is recorded for Applied BioMath.

What industry is Applied BioMath in?

Applied BioMath's product category is Quantitative Systems Pharmacology Consulting. Its primary akta.pro industry code is HLAIALAG, Clinical Pharmacology & Pharmacometrics (Modeling & Simulation), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ResearchsolutionsBiotechnology Case Study: Applied BioMathApplied BioMath deployed Research Solutions' Article Galaxy platform to streamline its access to scientific literature and accelerate drug discovery processes. The solution provides 24/7 integrated search and delivery of full-text articles, addressing the startup's need for efficiency as it grew beyond its initial research infrastructure.GlobeNewswireCertara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel TherapiesCertara acquired Applied BioMath, combining their quantitative systems pharmacology (QSP) expertise. The deal creates the industry's largest QSP team to industrialize biosimulation for drug development. The combined portfolio aims to enhance decision-making across preclinical to clinical phases.GlobeNewswireCertara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel TherapiesCertara acquired Applied BioMath, combining their quantitative systems pharmacology (QSP) expertise. The combined team aims to industrialize QSP biosimulation for drug development, with nine out of ten new therapies failing due to efficacy or toxicity. The acquisition expands Certara's biosimulation portfolio.PR NewswireApplied BioMath, LLC Named a Top Place to Work in Massachusetts by The Boston GlobeApplied BioMath, LLC announced it was named one of the Top Places to Work in Massachusetts in The Boston Globe's 16th annual employee-based survey. Over 90% of the company's employees completed the anonymous survey, which assessed categories including company direction, management, workplace experience, and pay and benefits, with the company scoring among the highest in overall workplace experience. Founded in 2013, Applied BioMath has grown from three founders to over 50 employees, offering a hybrid workforce with employees based in Concord, MA, and remote team members across the United States and Canada.PR NewswireApplied BioMath, LLC Presents Quantitative Systems Pharmacology Model of T-cell Engagers for Solid Tumors at the Society for Immunotherapy of Cancer Annual MeetingApplied BioMath announced its participation at the 38th Annual Society for Immunotherapy of Cancer meeting in San Diego, where it will present a Quantitative Systems Pharmacology model developed for CDR404, a T-cell engager targeting solid tumors. The QSP model is designed to support first-in-human trial design by predicting safe and therapeutic dose ranges for the antibody-based therapy that binds to MAGE-A4 peptide on cancer cells and CD3 on T-cells. The company stated that QSP modeling can help progress therapeutics with complex mechanisms through the R&D pipeline by optimizing molecule design and guiding clinical trial decisions.PR NewswireMarissa Renardy, PhD, of Applied BioMath, Receives ISoP Emerging Scientist AwardApplied BioMath announced that Marissa Renardy, PhD, Principal Scientist at the company received ISoP's Emerging Scientist Award, which recognizes early-career scientists for impact in pharmacometrics and related scientific fields. Dr. Renardy will be recognized at the ACoP14 opening session and ISoP awards ceremony on November 5, 2023. She joined Applied BioMath in 2020 and has supported projects involving various therapeutic modalities including antibody drug conjugates, cell engagers, and cell therapies.PR NewswireApplied BioMath, LLC Hosts 6th Annual Quantitative Systems Pharmacology SummitApplied BioMath announced the full speaker lineup for its 6th annual Quantitative Systems Pharmacology Summit scheduled for October 12, 2023, in Cambridge, Massachusetts. The summit will feature speakers from major pharmaceutical companies including GSK, Pfizer, Takeda, Janssen, EQRx, Seismic Therapeutics, and EMD Serono, as well as representatives from the U.S. Food and Drug Administration and academic institutions such as Harvard Medical School. The event aims to bring together the QSP community to discuss advances in model-informed drug development.PR NewswireApplied BioMath, LLC Presents Mathematical Modeling to Optimize Therapeutic Window at the 14th Annual World Bispecific SummitApplied BioMath announced its participation in the 14th Annual World Bispecific Summit taking place October 2-4, 2023 in Boston, MA, where Dr. Fei Hua will present on using mathematical modeling to optimize the therapeutic window for bispecific molecules. The presentation will demonstrate how mechanistic PK/PD models can capture binding and avidity biophysics to guide compound selection and clinical translation. The company states that mathematical modeling approaches provide competitive advantages by testing hypotheses faster than traditional methods for complex bispecific and multispecific therapeutics.PR NewswireApplied BioMath, LLC Announces Speaker Lineup for Quantitative Systems Pharmacology Summit Cambridge 2023Applied BioMath announced the speaker lineup for its sixth annual Quantitative Systems Pharmacology Summit, scheduled for October 12, 2023, in Cambridge, Massachusetts. The summit will feature researchers from organizations including GSK, EQRx, Takeda, and Janssen presenting on mathematical modeling approaches to support drug development programs. An open abstract submission is available for participants in computational biology fields, with awards for the top three academic posters.